Contact
searchSearch
HMP Global
Tools

Botulinum Toxin Medicare Documentation Checklist

Practical Considerations Under Updated Medicare Local Coverage Determinations (LCDs)

11/06/2026

This checklist summarizes key documentation considerations under the updated Medicare LCDs for botulinum toxin and includes examples of objective measures to help clinicians review whether their documentation reflects LCD requirements.

This program was independently developed with funding from AbbVie Medical Affairs + Health Impact.

This program is intended for educational purposes and does not provide coding, billing, reimbursement, or legal advice. Healthcare professionals (HCPs) should consult the applicable Medicare Administrative Contractor (MAC), related billing and coding articles, and their own reimbursement or legal professionals for guidance specific to their practice.

Related Content

a man holds his head in his hands
News
Eptinezumab Improves Migraine-Related Cognitive Symptoms in INFUSE Study
04/20/2026
Maria Mantas
Real-world data presented at the American Academy of Neurology (AAN) 2026 Annual Meeting reported improvements in migraine-related cognitive symptoms with eptinezumab (VYEPTI).
Real-world data presented at the American Academy of Neurology (AAN) 2026 Annual Meeting reported improvements in migraine-related cognitive symptoms with eptinezumab (VYEPTI).
Real-world data presented at the...
04/20/2026
Neurology
A woman lies on the couch holding an ice pack to her head
News
Migraine Nearly Doubles Depression and Anxiety Risk in Cohort Study
03/10/2026
Brionna Mendoza
Patients with migraine are at 2 times the risk for depression or anxiety compared to those without migraine, according to a large nationwide Swedish cohort study published in The Journal of Headache and Pain.
Patients with migraine are at 2 times the risk for depression or anxiety compared to those without migraine, according to a large nationwide Swedish cohort study published in The Journal of Headache and Pain.
Patients with migraine are at 2...
03/10/2026
Psych Congress Network
a printed test, pencil, and clock on a desk
Quiz
Addressing Non-Response in Migraine Treatment
03/09/2026
Maria Mantas
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
03/09/2026
Neurology
a mother and daughter sit at a table
News
Fremanezumab Reduces Migraine Days in Pediatric Episodic Migraine
01/30/2026
Maria Mantas
In a recent randomized, placebo-controlled trial, researchers found that fremanezumab significantly reduced monthly migraine days compared with placebo in children and adolescents with episodic migraine. 
In a recent randomized, placebo-controlled trial, researchers found that fremanezumab significantly reduced monthly migraine days compared with placebo in children and adolescents with episodic migraine. 
In a recent randomized,...
01/30/2026
Neurology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use